{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:06:26Z","timestamp":1783613186661,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,27]]},"DOI":"10.7759\/cureus.14719","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T18:16:57Z","timestamp":1619547417000},"source":"Crossref","is-referenced-by-count":5,"title":["Association Between Myasthenia Gravis and Systemic Lupus Erythematosus as a Comorbid State"],"prefix":"10.7759","author":[{"given":"Moeez","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Riad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiman","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihan A","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"[Transforming growth factor beta (TGF-beta): its structure, function, and role in the pathogenesis of systemic lupus erythematosus]","volume":"62","author":"Stepie\u0144-Wyrobiec O","year":"2008","unstructured":"Stepie\u0144-Wyrobiec O, Hrycek A, Wyrobiec G. [Transforming growth factor beta (TGF-beta): its structure, function, and role in the pathogenesis of systemic lupus erythematosus]. Postepy Hig Med Dosw (Online). 2008, 62:688-93.","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308095138","article-title":"Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus","volume":"17","author":"Hostmann A","year":"2008","unstructured":"Hostmann A, Jacobi AM, Mei H, Hiepe F, D\u00f6rner T. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus. 2008, 17:1064-9. 10.1177\/0961203308095138","journal-title":"Lupus"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1136\/ard.59.3.230","article-title":"Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus","volume":"59","author":"McDonagh JE","year":"2000","unstructured":"McDonagh JE, Isenberg DA. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis. 2000, 59:230-2.","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0459-6","article-title":"Coeliac disease in systemic lupus erythematosus: a case report","volume":"28","author":"Hrycek A","year":"2008","unstructured":"Hrycek A, Siekiera U. Coeliac disease in systemic lupus erythematosus: a case report. Rheumatol Int. 2008, 28:491-3. 10.1007\/s00296-007-0459-6","journal-title":"Rheumatol Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.9.1044","article-title":"Thymoma-associated systemic lupus erythematosus, exacerbating after thymectomy. A case report and review of the literature","volume":"39","author":"Boonen A","year":"2000","unstructured":"Boonen A, Rennenberg R, van der Linden S. Thymoma-associated systemic lupus erythematosus, exacerbating after thymectomy. A case report and review of the literature. Rheumatology (Oxford). 2000, 39:1044-6. 10.1093\/rheumatology\/39.9.1044","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200601000-00004","article-title":"High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study","volume":"331","author":"Sthoeger Z","year":"2006","unstructured":"Sthoeger Z, Neiman A, Elbirt D, et al.. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study. Am J Med Sci. 2006, 331:4-9. 10.1097\/00000441-200601000-00004","journal-title":"Am J Med Sci"},{"key":"ref7","article-title":"Acute respiratory failure in patients with Guillain-Barr\u00e9 syndrome and myasthenic crisis treated with plasmapheresis in the intensive care unit","volume":"118","author":"Szczeklik W","year":"2008","unstructured":"Szczeklik W, Jankowski M, Wegrzyn W, et al.. Acute respiratory failure in patients with Guillain-Barr\u00e9 syndrome and myasthenic crisis treated with plasmapheresis in the intensive care unit. Pol Arch Med Wewn. 2008, 118:239-42.","journal-title":"Pol Arch Med Wewn"},{"key":"ref8","article-title":"[Clinical manifestation and immunological diagnostics of myasthenia gravis and Lambert\u2011Eaton syndrome (usefulness of the following antibodies: anti\u2011AChR, anti\u2011titin, anti\u2011MuSK and against calcic canal proteins of Ach secretion)]","volume":"4","author":"Strugalska\u2011Cynowska MH","year":"2008","unstructured":"Strugalska\u2011Cynowska MH. [Clinical manifestation and immunological diagnostics of myasthenia gravis and Lambert\u2011Eaton syndrome (usefulness of the following antibodies: anti\u2011AChR, anti\u2011titin, anti\u2011MuSK and against calcic canal proteins of Ach secretion)]. Polski Przegl\u0105d Neurologiczny. 2008, 4:75-6.","journal-title":"Polski Przegl\u0105d Neurologiczny"},{"key":"ref9","article-title":"Myasthenia gravis","volume":"88","author":"Vincent A","year":"2002","unstructured":"Vincent A, Drachman DB. Myasthenia gravis. Adv Neurol. 2002, 88:159-88.","journal-title":"Adv Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/BF00915723","article-title":"Immunopathogenesis and treatment of myasthenia gravis","volume":"7","author":"Levinson AI","year":"1987","unstructured":"Levinson AI, Zweiman B, Lisak RP. Immunopathogenesis and treatment of myasthenia gravis. J Clin Immunol. 1987, 7:187-97. 10.1007\/BF00915723","journal-title":"J Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1966.00470090026003","article-title":"Myasthenia gravis and systemic lupus erythematosus","volume":"14","author":"Wolf SM","year":"1966","unstructured":"Wolf SM, Barrows HS. Myasthenia gravis and systemic lupus erythematosus. Arch Neurol. 1966, 14:254-8. 10.1001\/archneur.1966.00470090026003","journal-title":"Arch Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1989.tb01353.x","article-title":"Myasthenia gravis and lupus erythematosus","volume":"28","author":"Ciaccio M","year":"1989","unstructured":"Ciaccio M, Parodi A, Rebora A. Myasthenia gravis and lupus erythematosus. Int J Dermatol. 1989, 28:317-20. 10.1111\/j.1365-4362.1989.tb01353.x","journal-title":"Int J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.12890\/2014_000020","article-title":"Development of myasthenia gravis in systemic lupus erythematosus","volume":"1","author":"Kigawa N","year":"2014","unstructured":"Kigawa N, Pineau C, Clarke AE, Nashi E, Vinet \u00c9, Veilleux M, Bernatsky S. Development of myasthenia gravis in systemic lupus erythematosus. Eur J Case Rep Intern Med. 2014, 1:25685752. 10.12890\/2014_000020","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli MN","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8:475-90. 10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0814","article-title":"Clinical characteristics of pediatric myasthenia: a surveillance study","volume":"132","author":"VanderPluym J","year":"2013","unstructured":"VanderPluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical characteristics of pediatric myasthenia: a surveillance study. Pediatrics. 2013, 132:939-44. 10.1542\/peds.2013-0814","journal-title":"Pediatrics"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311412096","article-title":"Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus","volume":"20","author":"Pineles D","year":"2011","unstructured":"Pineles D, Valente A, Warren B, Peterson MG, Lehman TJ, Moorthy LN. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus. 2011, 20:1187-92. 10.1177\/0961203311412096","journal-title":"Lupus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.6.825","article-title":"Systemic lupus erythematosus and invasive thymoma: report of two cases","volume":"43","author":"Steven MM","year":"1984","unstructured":"Steven MM, Westedt ML, Eulderink F, Hazevoet HM, Dijkman JH, Cats A. Systemic lupus erythematosus and invasive thymoma: report of two cases. Ann Rheum Dis. 1984, 43:825-8. 10.1136\/ard.43.6.825","journal-title":"Ann Rheum Dis"},{"key":"ref18","article-title":"Autoimmunity and autoimmune disease","author":"Anaya JM","year":"2005","unstructured":"Anaya JM, Shoenfeld Y, Correa PA. Garcia Carasco M, Cervera R. Autoimmunity and autoimmune disease. CIB, Medellin, Colombia; 2005."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.05.001","article-title":"Myasthenia Gravis: paradox versus paradigm in autoimmunity","volume":"52","author":"Berrih-Aknin S","year":"2014","unstructured":"Berrih-Aknin S. Myasthenia Gravis: paradox versus paradigm in autoimmunity. J Autoimmun. 2014, 52:1-28. 10.1016\/j.jaut.2014.05.001","journal-title":"J Autoimmun"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/s1568-9972(03)00006-5","article-title":"The epidemiology of autoimmune diseases","volume":"2","author":"Cooper GS","year":"2003","unstructured":"Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003, 2:119-25. 10.1016\/s1568-9972(03)00006-5","journal-title":"Autoimmun Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(89)90245-4","article-title":"The mosaic of autoimmunity","volume":"10","author":"Shoenfeld Y","year":"1989","unstructured":"Shoenfeld Y, Isenberg DA. The mosaic of autoimmunity. Immunol Today. 1989, 10:123-6. 10.1016\/0167-5699(89)90245-4","journal-title":"Immunol Today"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu A","year":"2015","unstructured":"Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE. Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity. 2015, 48:362-8. 10.3109\/08916934.2015.1030614","journal-title":"Autoimmunity"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2010.539307","article-title":"Frequency of autoimmune diseases in myasthenia gravis: a systematic review","volume":"121","author":"Mao ZF","year":"2011","unstructured":"Mao ZF, Yang LX, Mo XA, et al.. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci. 2011, 121:121-9. 10.3109\/00207454.2010.539307","journal-title":"Int J Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.110","article-title":"Myasthenia gravis and associated diseases","volume":"6","author":"Tanovska N","year":"2018","unstructured":"Tanovska N, Novotni G, Sazdova-Burneska S, et al.. Myasthenia gravis and associated diseases. Open Access Maced J Med Sci. 2018, 6:472-8. 10.3889\/oamjms.2018.110","journal-title":"Open Access Maced J Med Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12310","article-title":"The autoimmune spectrum of myasthenia gravis: a Swedish population-based study","volume":"277","author":"Fang F","year":"2015","unstructured":"Fang F, Sveinsson O, Thormar G, et al.. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med. 2015, 277:594-60. 10.1111\/joim.12310","journal-title":"J Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1995.tb00432.x","article-title":"Associated autoimmune diseases in myasthenia gravis. A population-based study","volume":"91","author":"Christensen PB","year":"1995","unstructured":"Christensen PB, Jensen TS, Tsiropoulos I, et al.. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol Scand. 1995, 91:192-5. 10.1111\/j.1600-0404.1995.tb00432.x","journal-title":"Acta Neurol Scand"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6335-z","article-title":"The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature","volume":"259","author":"Jallouli M","year":"2012","unstructured":"Jallouli M, Saadoun D, Eymard B, et al.. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol. 2012, 259:1290-7. 10.1007\/s00415-011-6335-z","journal-title":"J Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308093463","article-title":"Myasthenia gravis associated with lupus nephritis","volume":"17","author":"Lee H","year":"2008","unstructured":"Lee H, Chen W, Su K, Chou C, Tsai C. Myasthenia gravis associated with lupus nephritis. Lupus. 2008, 17:860-1. 10.1177\/0961203308093463","journal-title":"Lupus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2383","article-title":"The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis","volume":"108","author":"Meraouna A","year":"2006","unstructured":"Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tallaksen C, Berrih-Aknin S. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood. 2006, 108:432-40. 10.1182\/blood-2005-06-2383","journal-title":"Blood"},{"key":"ref30","article-title":"The role of chemokines in neoplastic diseases","volume":"13","author":"Mazur G","year":"2004","unstructured":"Mazur G, Jasku\u0142a E, Kryczek I. The role of chemokines in neoplastic diseases. Adv Clin Exp Med. 2004, 13:315-25.","journal-title":"Adv Clin Exp Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01265","article-title":"Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update","volume":"10","author":"Lotfi N","year":"2019","unstructured":"Lotfi N, Thome R, Rezaei N, Zhang GX, Rezaei A, Rostami A, Esmaeil N. Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update. Front Immunol. 2019, 10:1265. 10.3389\/fimmu.2019.01265","journal-title":"Front Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review","volume":"15","author":"Bernard C","year":"2016","unstructured":"Bernard C, Frih H, Pasquet F, et al.. Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev. 2016, 15:82-9. 10.1016\/j.autrev.2015.09.005","journal-title":"Autoimmun Rev"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.74","article-title":"Thymoma and autoimmunity","volume":"8","author":"Shelly S","year":"2011","unstructured":"Shelly S, Agmon-Levin N, Altman A, Shoenfeld Y. Thymoma and autoimmunity. Cell Mol Immunol. 2011, 8:199-202. 10.1038\/cmi.2010.74","journal-title":"Cell Mol Immunol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s0091-6749(99)70431-8","article-title":"Long-term immunologic effects of thymectomy in patients with myasthenia gravis","volume":"103","author":"Gerli R","year":"1999","unstructured":"Gerli R, Paganelli R, Cossarizza A, et al.. Long-term immunologic effects of thymectomy in patients with myasthenia gravis. J Allergy Clin Immunol. 1999, 103:865-72. 10.1016\/s0091-6749(99)70431-8","journal-title":"J Allergy Clin Immunol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-53145-4_5","article-title":"Neuromuscular emergencies in the neuroscience intensive care unit","author":"Chandrasekaran PN","year":"2020","unstructured":"Chandrasekaran PN, Pandey A, Idiculla PS. Neuromuscular emergencies in the neuroscience intensive care unit. Neuromuscular Urgencies and Emergencies. Arora N, Govindarajan R, Kataria S, Nattanmai Chandrasekaran P (ed): Springer, Cham, Switzerland; 2020. 10.1007\/978-3-030-53145-4_5"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2007.06.044","article-title":"Prolactin may be a promising therapeutic target for myasthenia gravis: hypothesis and importance","volume":"70","author":"Yang M","year":"2008","unstructured":"Yang M, Huang L, Liu W, Sheng Z, Xie H, Liao E. Prolactin may be a promising therapeutic target for myasthenia gravis: hypothesis and importance. Med Hypotheses. 2008, 70:1017-20. 10.1016\/j.mehy.2007.06.044","journal-title":"Med Hypotheses"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308098191","article-title":"Lupus and T cells","volume":"18","author":"La Cava A","year":"2009","unstructured":"La Cava A. Lupus and T cells. Lupus. 2009, 18:196-201. 10.1177\/0961203308098191","journal-title":"Lupus"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.07.007","article-title":"Systemic lupus erythematosus-myasthenia gravis overlap syndrome: presentation and treatment depend on prior thymectomy","volume":"194","author":"Minchenberg SB","year":"2018","unstructured":"Minchenberg SB, Chaparala G, Oaks Z, Banki K, Perl A. Systemic lupus erythematosus-myasthenia gravis overlap syndrome: presentation and treatment depend on prior thymectomy. Clin Immunol. 2018, 194:100-4. 10.1016\/j.clim.2018.07.007","journal-title":"Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/53639-association-between-myasthenia-gravis-and-systemic-lupus-erythematosus-as-a-comorbid-state","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:47Z","timestamp":1707506867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/53639-association-between-myasthenia-gravis-and-systemic-lupus-erythematosus-as-a-comorbid-state"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.14719","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,27]]}}}